NASDAQ
1.06USD
+0.00 (+0.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
23.6K
P/E
—
EPS
—
Beta
0.44
52W range
0.861-1297.5
Day range
0.98–1.11
Open
1.04
Prev close
1.06
Volume
114.7K
Avg volume
303.6K
Dividend
0.00
IPO
2025-07-14
https://www.globenewswire.com/news-release/2026/07/31/3337078/0/en/profusa-announces-signing-of-option-agreement-for-the-acquisition-of-a-commercial-stage-diagnostics-company-g3-vision-labs.html · 7/31/2026+0.60
https://www.benzinga.com/news/health-care/26/01/49973068/profusa-stock-spikes-as-lumee-system-targets-research-market · 1/16/2026+0.60
https://www.globenewswire.com/news-release/2025/10/15/3167073/0/en/Profusa-Expands-Sales-Footprint-with-New-Distributor-for-Lumee-Oxygen-Platform-in-Europe.html · 10/15/2025+0.80
Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors. These innovative devices, exemplified by their Lumee™ Oxygen Platform, are designed for uninterrupted observation of internal physiological markers. By leveraging artificial intelligence, Profusa translates this constant stream of data into actionable health insights, primarily to empower individuals and clinicians in the management of persistent health challenges like diabetes and critical limb ischemia.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
